Gamma Delta T Cell Platform
Solid Tumors
Key Facts
About Adicet Bio
Adicet Bio is focused on delivering best-in-class, allogeneic gamma delta T cell therapies, offering a potentially superior alternative to traditional alpha beta CAR-T. Its proprietary platform harnesses the innate tissue-homing, MHC-independent tumor recognition, and favorable safety profile of gamma delta 1 T cells to target both solid tumors and autoimmune diseases. The company is publicly traded and is advancing its lead program, prula-cel, through clinical development with a focus on achieving key milestones in 2026.
View full company profileAbout Adicet Bio
Adicet Bio is focused on delivering best-in-class, allogeneic gamma delta T cell therapies, offering a potentially superior alternative to traditional alpha beta CAR-T. Its proprietary platform harnesses the innate tissue-homing, MHC-independent tumor recognition, and favorable safety profile of gamma delta 1 T cells to target both solid tumors and autoimmune diseases. The company is publicly traded and is advancing its lead program, prula-cel, through clinical development with a focus on achieving key milestones in 2026.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| GSK4362676 | GSK plc | Phase 1 |
| ABBV-154 | AbbVie | Phase 1 |
| TAK-981 | Takeda Pharmaceutical | Phase 1/2 |
| TAK-676 | Takeda Pharmaceutical | Phase 1 |
| TAK-573 | Takeda Pharmaceutical | Phase 1 |
| TAK-164 | Takeda Pharmaceutical | Phase 1 |
| SHR-1316 | Jiangsu Hengrui Medicine | Phase 1/2 |
| BAY 2927088 | Bayer | Phase 1 |
| ASP1929 | Astellas Pharma | Phase 2 |
| IBI188 | Innovent Biologics | Phase 1 |
| Bispecific Antibody | Akeso | Phase 1/2 |
| CSPC-DM02 | CSPC Pharmaceutical Group Limited | Phase 2 |